| Literature DB >> 29114512 |
Jennifer Bogulski1, Steven Gonser2, Doug Bush3, Rachel Bugner4, Lindsey Clark1, Lisa Farrell1, Kristen Swanson1, Michael David Ross1.
Abstract
As recreational running continues to gain popularity, more individuals are seeking ways to improve running performance. RunSmart is a running intervention program designed to enhance a runner's form. In addition to correcting flaws in a runner's form, RunSmart offers the opportunity for runners to continue a regular regimen while slowly integrating changes in form. The purpose of this case series was twofold: to determine if the RunSmart program coincides with improvements in oxygen consumption (VO2), a variable often associated with better running performance times, and to evaluate the RunSmart program in regard to enhancing gait biomechanics. Five recreational runners volunteered to participate in this program. Subjects initially reported to the clinic for an initial submaximal VO2 treadmill test and lower extremity biomechanical analysis. After the initial testing session, each subject attended one session of one-on-one individualized RunSmart instruction per week for 6 weeks. At the first RunSmart session, subjects received a biomechanical analysis to determine their foot strike pattern and areas of muscular weakness and range of motion limitations. Throughout the 6-week run-ning program, participants ran 5 days every week for predetermined times each day; 2 runs every week were designated as interval training runs. Subjects then underwent a follow-up submaximal VO2 treadmill test and lower extremity biomechanical analysis at the end of 6 weeks. Descriptive statistics were used to assess data pertaining to VO2 and biomechanical analysis and compare initial and follow-up testing sessions. Following completion of the RunSmart program, subjects demonstrated improvements in VO2 and also improved several biomechanical factors related to the lower extremity running gait. Based on the results from this case series, the RunSmart training program may have the potential to change a runner's form and improve VO2, thus resulting in improved distance running times. However, this is speculation given the nonexperimental nature of this case series. Future research on this topic should include a greater number of participants in randomized controlled trials on injury prevention and running efficiency.Entities:
Keywords: Biomechanics; Oxygen consumption; Running
Year: 2017 PMID: 29114512 PMCID: PMC5667624 DOI: 10.12965/jer.1734994.497
Source DB: PubMed Journal: J Exerc Rehabil ISSN: 2288-176X
Target heart rate zones, weekly running schedule, and participant daily running log
Physical characteristics of participants
| Subject No. | Age (yr) | Sex | Height (cm) | Weight (kg) |
|---|---|---|---|---|
| 1 | 30 | Male | 152.4 | 90.7 |
| 2 | 29 | Female | 172.7 | 68.5 |
| 3 | 40 | Male | 172.7 | 88.9 |
| 4 | 34 | Male | 175.6 | 84.8 |
| 5 | 37 | Male | 180.3 | 112.9 |
| Mean±SD | 34±4.6 | 170.7±10.7 | 89.2±15.9 |
SD, standard deviation.
Oxygen consumption for each of the 3 stages during initial and follow-up testing, as well as the threshold oxygen consumption (VO2) at follow-up testing; all subjects except subject 4 improved the speed at which they reached threshold values
| Subject No. | Initial VO2 submaximal (mL/min) | Follow-up VO2 submaximal (mL/min) | |||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| Stage 1 | Stage 2 | Stage 3 | Stage 1 | Stage 2 | Stage 3 | Threshold | |
| 1 | 2,481.2 | 2,816.0 | 2,895.3 | 2,384.0 | 2,844.0 | 3,226.0 | 3,337.0 |
|
| |||||||
| 2 | 2,292.3 | 2,681.3 | 3,136.1 | 2,701.4 | 3,003.4 | 3,186.0 | 3,186.0 |
|
| |||||||
| 3 | 2,191.1 | 2,883.2 | 3,105.3 | 2,377.0 | 2,890.6 | 3,266.5 | 3,693.8 |
|
| |||||||
| 4 | 3,860.1 | 4,234.6 | 4,372.9 | 4,123.5 | 4,196.4 | 4,261.9 | 4,261.9 |
|
| |||||||
| 5 | 2,016.5 | 2,170.0 | 2,213.3 | 2,482.9 | 2,527.4 | 2,577.0 | 2,685.6 |
|
| |||||||
| Mean±SD | 2,568.2±741.5 | 2,957.0±766.0 | 3,144.6±780.0 | 2,813.8±743.8 | 3,092.4±641.9 | 3,303.5±605.7 | 3,432.9±588.2 |
Percent of the threshold oxygen consumption reached at each of the three stages of testing
| Subject No. | Initial testing | Follow-up testing | ||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Stage 1 | Stage 2 | Stage 3 | Stage 1 | Stage 2 | Stage 3 | |
| 1 | 85.7 | 97.3 | 100 | 71.4 | 85.2 | 74.9 |
|
| ||||||
| 2 | 73.1 | 85.5 | 100 | 84.8 | 94.3 | 100 |
|
| ||||||
| 3 | 70.6 | 92.9 | 100 | 64.4 | 78.3 | 88.4 |
|
| ||||||
| 4 | 88.3 | 96.8 | 100 | 96.8 | 98.5 | 100 |
|
| ||||||
| 5 | 91.1 | 98.0 | 100 | 92.5 | 94.1 | 95.0 |
|
| ||||||
| Mean±SD | 81.2±9.3 | 94.1±5.2 | 100±0 | 82.0±13.8 | 90.1±8.2 | 91.7±10.5 |
SD, standard deviation.
Maximal angles of ankle dorsiflexion, knee extension, knee flexion and hip flexion during initial and follow-up testing
| Subject No. | Initial testing | Follow-up testing | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| Ankle dorsiflexion (°) | Knee extension (°) | Knee flexion (°) | Hip flexion (°) | Ankle dorsiflexion (°) | Knee extension (°) | Knee flexion (°) | Hip flexion (°) | |
| 1 | 10.7 | 173.3 | 105.9 | 32.2 | 2.7 | 163.1 | 111.4 | 42.4 |
|
| ||||||||
| 2 | 9.6 | 170.5 | 93.9 | 31.4 | −15.3 | 169.3 | 114.4 | 41.1 |
|
| ||||||||
| 3 | 7.7 | 177.5 | 107.6 | 26.8 | −12.3 | 168.9 | 105.7 | 34.8 |
|
| ||||||||
| 4 | 7.8 | 174.1 | 93.7 | 27.9 | −4.2 | 170.7 | 103.2 | 38.5 |
|
| ||||||||
| 5 | 10.4 | 171.9 | 89.9 | 29.5 | −5.9 | 164.9 | 105.1 | 32.8 |
|
| ||||||||
| Mean±SD | 9.2±1.4 | 173.5±2.6 | 98.2±8.0 | 29.6±2.3 | −7.0±7.1 | 167.4±3.2 | 108.0±4.7 | 37.9±4.1 |
SD, standard deviation.